BioMedNewsBreaks – Revelation Biosciences Inc. (NASDAQ: REVB) Secures ~$6.2M in Public Offering

Revelation Biosciences (NASDAQ: REVB), a life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, recently announced the closing of its public offering. The offering consisted of 128,470 shares of the company’s common stock and 1,236,530 pre-funded warrants to purchase shares of common stock, together with warrants to purchase up to 2,730,000 shares of its common stock, at an offering price to the public of $4.53 per share and associated warrant, or $4.5299 per pre-funded warrant and associated warrant. The warrants have an exercise price of $4.53 per share and are exercisable upon issuance, expiring five years following the date of issuance. Roth Capital Partners acted as sole placement agent for the offering.

To view the full press release, visit https://ibn.fm/22dSL

About Revelation Biosciences Inc.

Revelation Biosciences is a life sciences company focused on harnessing the power of trained immunity for the prevention and treatment of disease using its proprietary formulation, Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including GEMINI-SSI as a prevention for hospital acquired infection, GEMINI-AKI as a prevention for acute kidney injury, as well as GEMINI-CKD for the treatment of chronic kidney disease. For more information about the company, visit www.RevBiosciences.com.

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.